众生药业：公司昂拉地韦片和昂拉地韦颗粒两项III期临床试验正在积极推进中，目前已完成全部参与者入组

Core Viewpoint - The company is actively advancing its clinical trials for two influenza treatments aimed at different age groups, with a focus on embracing new technologies to enhance patient care [2] Group 1: Clinical Trials - The company is conducting two Phase III clinical trials: one for the treatment of adolescents aged 12-17 with uncomplicated type A influenza using Anglatide tablets, and another for children aged 2-11 using Anglatide granules [2] - All participant recruitment for the clinical trials has been completed, indicating progress towards the next stages of research [2] Group 2: Technological Integration - The company emphasizes the importance of integrating new technologies to explore their potential in improving treatment options for patients [2] - There is a commitment to complete the relevant research and submit applications for drug approval as soon as possible, aiming to provide more treatment choices for patients [2]